Navigation Links
Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
Date:9/6/2007

NEW YORK, Sept. 6 /PRNewswire/ -- Globally, approximately 418 billion people are currently infected with hepatitis, and the unrecognized importance, danger, and costs of hepatitis in the 21st century cannot be understated or underestimated, according to Global Hepatitis Strategies, a new report by Kalorama Information.

Paradoxically, despite the obvious crisis, world governments are not taking the necessary steps to contain hepatitis. Yet the incidence and prevalence of hepatitis have begun to rise in certain parts of the global community, and even industrialized nations are lacking hepatitis control policies. Moreover, there is a greater crisis in hepatitis screening, diagnosis, and treatment emerging, particularly in those areas where HIV/AIDS is becoming more prevalent.

Kalorama Information estimates that the theoretical global market for all hepatitis testing products and therapeutics in 2006, assuming that aggressive screening were to be conducted, would be $3.3 trillion, with the western Pacific and southeast Asia showing the greatest need. However, the estimated realistic market potential for the various global regions for 2006, based on their currently reported hepatitis status and pricing structure, fell far short, reaching just $326 million.

"The strategic concept of hepatitis diagnosis and therapy is one of the most insufficiently recognized areas that the healthcare industry has ever seen," notes Kenneth. G. Krul, PhD, the report's author. "Governments, with the exception of a limited few, seem unable or unwilling to devise comprehensive hepatitis containment and prevention policies. In order to cope with the challenges and opportunities of hepatitis diagnostics and therapeutics, companies must think on a global basis, focusing on three points for the development of strategy: potential market, epidemiology (hepatitis patient trends), and technology."

Global Hepatitis Strategies focuses on the factors that influence policy aspects of hepatitis, the options presented, the factors associated with strategic market development of hepatitis diagnostics and therapeutics, and prospects for the future. The report analyzes strategic market effects of epidemiology, market potential and technology, trends in epidemiology, and social/political attitudes towards hepatitis. This report can be purchased directly from Kalorama Information by visiting: https://www.kaloramainformation.com/Global-Hepatitis-Strategies-1517677. It is also available at MarketResearch.com.

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Gala Biotech among companies sold for $3.3 billion
2. Is your brand worth billions?
3. Fiserv makes over $1 billion, but profits decline
4. GE completes $1.2 billion acquisition
5. $1.45 billion judgment against Morgan Stanley sends message revisit e-mail retention policies
6. Alzheimers drug market to hit $5.5 billion by 2009, study says
7. How a Midwestern girl became the CEO of a multi-billion-dollar software company
8. Billions with a B for R&D
9. Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs
10. Southwestern lab selects Third Wave reagents for Hepatitis tests
11. Third Wave releases reagents for Hepatitis C testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
(Date:4/27/2016)... ... , ... Shimadzu Scientific Instruments (SSI) will be showcasing a ... and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, ... by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of Directors of ... John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, ... leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton ...
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology ... development initiatives for potential stem cell protocol management for 2016 – 2020. , ... meeting to establish a working agenda and foster initiatives to promote stem cell research ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):